Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Kardiologia polska

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5603/KP.a2017.0116PMID 28612911
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What Role for Glycoprotein IIb/IIIa Inhibition in Contemporary Coronary Intervention?

  2015cited by this paper
• Comparison of primary coronary percutaneous coronary intervention between Diabetic Men and Women with acute myocardial infarction

  2015cited by this paper
• Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI).

  2015cited by this paper
• Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).

  2015cited by this paper
• Platelet Glycoprotein IIb/IIIa Inhibitor Tirofiban Ameliorates Cardiac Reperfusion Injury.

  2015cited by this paper
• Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns

  2015cited by this paper
• Updates to the ACCF/AHA and ESC STEMI and NSTEMI guidelines: putting guidelines into clinical practice.

  2015cited by this paper
• Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.

  2015cited by this paper
• A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy.

  2014cited by this paper
• The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.

  2013cited by this paper
• Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Stemi: Thrombus charateristics and no reflow phoenomenon

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Effects of Coronary Arterial Injection of Tirofiban on Diabetes Mellitus Complicated with Acute Myocardial Infarction in the Elderly.

  2013cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2012cited by this paper
• [Analysis of the clinical data of patients with acute coronary syndrome complicated by hemorrhage during hospitalization].

  2012cited by this paper
• Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review

  2012cited by this paper
• Evolution of myocardial perfusion during primary angioplasty in spontaneously reperfused infarct-related artery: impact on long-term clinical outcomes and left ventricular function recovery.

  2011cited by this paper
• 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.

  2011cited by this paper
• Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

  2010cited by this paper
• Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003).

  2008cited by this paper
• Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.

  2007cited by this paper
• Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

  2003cited by this paper
• Current Concepts of the Pathogenesis of the Acute Coronary Syndromes

  2001influential reference
• Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase

  1988cited by this paper
• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  1987cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper

• Ticagrelor versus Clopidogrel, Drug of Choice for the Prevention of Stent Thrombosis after Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials

  2023cites this paper
• Efficacy and Safety of Clopidogrel Versus Ticagrelor as Part of Dual Antiplatelet Therapy in Acute Coronary Syndrome—A Systematic Review and Meta-analysis

  2022cites this paper
• Efeitos Terapêuticos da Tripla Antiagregação Plaquetária em Pacientes Femininas Idosas com Diabetes e Infarto Agudo do Miocárdio

  2021influential citation
• Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention

  2021cites this paper
• Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials.

  2020cites this paper
• Comparative efficacy and safety of antithrombotic therapy for transcatheter aortic valve replacement: a systematic review and network meta-analysis.

  2019cites this paper
• Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials.

  2019cites this paper
• Comparison of hemorrhages of different triple antiplatelet therapies in female patients of acute coronary syndrome associated with diabetes after percutaneous coronary intervention

  2019cites this paper
• Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention

  2018cites this paper
• Bleeding after Taking Dual Antiplatelets and NSAID Concurrently

  2018cites this paper
• Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation

  2018cites this paper
• Tikagrelor — więcej, powszechniej, wcześniej…

  2017cites this paper